---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-060563"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2025-04-30T23:59:59+00:00"
generated_at: "2026-05-23T02:08:45.496402+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Larimar Q1 net loss $29.3M; FDA open to accelerated approval using skin FXN as surrogate endpoint

## Summary
- Net loss $29.3M ($0.46 per share) vs $14.7M ($0.27) YoY; R&D spend rose to $26.6M on manufacturing and Phase 3 prep.
- Cash, equivalents and marketable securities $157.5M as of March 31, 2025; runway into Q2 2026.
- FDA agreed to consider skin FXN concentration as reasonably likely surrogate endpoint for accelerated approval.
- BLA submission planned by year-end 2025; global Phase 3 study to begin mid-2025 with U.S. and international sites.
- Adolescent PK run-in dosing completed; 50 mg OLE and adolescent data expected in September 2025 program update.

## SEC filing metadata
- accession: 0000950170-25-060563
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2025-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000095017025060563/0000950170-25-060563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000095017025060563/lrmr-20250430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-060563
- JSON: https://secwatch.observer/filing/0000950170-25-060563.json
- Plain text: https://secwatch.observer/filing/0000950170-25-060563.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.